Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 02, 2021

Liposomal Irinotecan Plus Fluorouracil and Leucovorin vs Fluorouracil and Leucovorin for Metastatic Biliary Tract Cancer After Progression on Gemcitabine Plus Cisplatin

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
Lancet Oncol 2021 Nov 01;22(11)1560-1572, C Yoo, KP Kim, JH Jeong, I Kim, MJ Kang, J Cheon, BW Kang, H Ryu, JS Lee, KW Kim, GK Abou-Alfa, BY Ryoo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading